ABUS vs. PHAR, ORIC, SVRA, PHAT, HROW, ZYME, CDMO, CALT, MLYS, and AVTE
Should you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Pharming Group (PHAR), ORIC Pharmaceuticals (ORIC), Savara (SVRA), Phathom Pharmaceuticals (PHAT), Harrow (HROW), Zymeworks (ZYME), Avid Bioservices (CDMO), Calliditas Therapeutics AB (publ) (CALT), Mineralys Therapeutics (MLYS), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical preparations" industry.
Pharming Group (NASDAQ:PHAR) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment, risk and valuation.
In the previous week, Arbutus Biopharma had 3 more articles in the media than Pharming Group. MarketBeat recorded 8 mentions for Arbutus Biopharma and 5 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.86 beat Arbutus Biopharma's score of 0.78 indicating that Arbutus Biopharma is being referred to more favorably in the news media.
Pharming Group has higher revenue and earnings than Arbutus Biopharma. Pharming Group is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.
Pharming Group presently has a consensus price target of $37.00, suggesting a potential upside of 308.84%. Arbutus Biopharma has a consensus price target of $4.33, suggesting a potential upside of 29.35%. Given Arbutus Biopharma's higher probable upside, equities research analysts clearly believe Pharming Group is more favorable than Arbutus Biopharma.
Pharming Group has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500.
Arbutus Biopharma received 414 more outperform votes than Pharming Group when rated by MarketBeat users. Likewise, 70.83% of users gave Arbutus Biopharma an outperform vote while only 50.00% of users gave Pharming Group an outperform vote.
Pharming Group has a net margin of -4.01% compared to Pharming Group's net margin of -572.81%. Arbutus Biopharma's return on equity of -4.61% beat Pharming Group's return on equity.
0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by insiders. Comparatively, 4.0% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Arbutus Biopharma beats Pharming Group on 10 of the 17 factors compared between the two stocks.
Get Arbutus Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arbutus Biopharma Competitors List
Related Companies and Tools
